On March 5, 2024 BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") reported that it has received a Notice of Allowance from the Japanese Patent Office for a Patent ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX (Press release, BioVaxys Technology, MAR 5, 2024, View Source [SID1234640829]). This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc. This Patent has already been issued in the US, and is currently pending in the EU.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DPX is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response.
The smallest dose of a currently approved vaccine is 0.1ml for Sanofi-Pasteur’s Fluzone Intradermal Quadrivalent vaccine. Low dose volume delivery of DPX formulated B-cell epitope is designed to be delivered in single dose as low as 50µL to 90 µL.
An epitope is the part of an antigen that the host’s immune system recognizes, eliciting the immune response to an invading pathogen. It specifically binds to the corresponding antigen receptor on the immune cell (such as a B-cell). Whereas T-cells protect people from getting infected by destroying cancerous and infected cells, B-cells produce antibodies to fight infection.
BioVaxys President and Chief Operating Officer Kenneth Kovan says "Expanding patent protection into major biopharma markets such as Japan further increases the value of the DPX platform for our Company. Having an ability to create low dose DPX+B cell epitope formulations is an attractive approach for packaging antigens for cancer immunotherapeutics and therapeutic vaccines such as for influenza, Zika virus, RSV, HSV, and many other viral or bacterial pathogens.
BioVaxys also is pleased to announce it filed an international patent application through the Patent Cooperation Treaty ("PCT") from two pending patent applications in the US related to methods of formulating DPX compositions that comprise both a lipid-based adjuvant (i.e. PAM) and a polyI:C polynucleotide adjuvant.
The PCT is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.